Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis
- PMID: 36335249
- DOI: 10.1007/s00405-022-07726-8
Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis
Abstract
Purpose: To investigate the efficacy of chemotherapy among intermediate-risk (stage II/T3N0) nasopharyngeal carcinoma (NPC) patients receiving radiotherapy (RT).
Methods: We identified stage II/T3N0 NPC patients who received radiotherapy with or without chemotherapy from the Surveillance, Epidemiology and End Results database (2004-2019). Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan-Meier method with log-rank test and Cox proportional hazards models to evaluate the efficacy of chemotherapy. Subgroup analysis was also conducted based on the baseline characteristics. Propensity score matching (PSM) was performed to balance the intergroup covariates.
Results: A total of 1623 patients were enrolled in the study, 1444 received chemoradiotherapy (CRT) and 179 received RT alone. CRT, compared to RT alone, was independently associated with a better OS (HR 0.57, 95% CI 0.45-0.71) and CSS (HR 0.55, 95% CI 0.39-0.79). After PSM, similar results were obtained, and CRT was superior to RT alone in terms of OS (HR 0.60, 95% CI 0.39-0.92) and CSS (HR 0.60, 95% CI 0.40-0.91). Subgroup analysis revealed that OS benefits from CRT were mainly observed in T0-2N1(HR 0.51, 95% CI 0.38-0.70) and T3N0 (HR 0.64, 95% CI 0.42-0.98) rather than T2N0 (HR 1.00, 95% CI 0.51-1.94). Interestingly, after PSM, OS benefits were still seen in T0-2N1 (HR 0.44, 95% CI 0.24-0.82), while not seen in T2N0 (HR 1.83, 95% CI 0.56-5.97) and T3N0 (HR 0.56, 95% CI 0.28-1.12).
Conclusion: For T0-2N1 NPC patients, CRT was superior to RT alone with better survival, whereas, for T2-3N0 patients, CRT was comparable to RT alone. Prospective large studies should be encouraged to verify the results.
Keywords: Chemotherapy; Nasopharyngeal carcinoma; Radiotherapy; SEER database.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.J Geriatr Oncol. 2023 Nov;14(8):101648. doi: 10.1016/j.jgo.2023.101648. Epub 2023 Oct 26. J Geriatr Oncol. 2023. PMID: 37897887
-
Efficacy of chemoradiotherapy in survival of stage Ⅳ nasopharyngeal carcinoma and establishment of a prognostic model.Oral Oncol. 2022 Aug;131:105927. doi: 10.1016/j.oraloncology.2022.105927. Epub 2022 Jun 6. Oral Oncol. 2022. PMID: 35679694
-
A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.Otolaryngol Head Neck Surg. 2021 Jul;165(1):93-103. doi: 10.1177/0194599820973241. Epub 2020 Nov 24. Otolaryngol Head Neck Surg. 2021. PMID: 33231508
-
The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma.Oral Oncol. 2020 Feb;101:104520. doi: 10.1016/j.oraloncology.2019.104520. Epub 2019 Dec 13. Oral Oncol. 2020. PMID: 31841883
-
A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.Front Oncol. 2022 Jul 12;12:843675. doi: 10.3389/fonc.2022.843675. eCollection 2022. Front Oncol. 2022. PMID: 35903695 Free PMC article.
Cited by
-
Diagnostic and prognostic nomograms for laryngeal carcinoma patients with lung metastasis: a SEER-based study.Eur Arch Otorhinolaryngol. 2024 Jun;281(6):3071-3082. doi: 10.1007/s00405-024-08608-x. Epub 2024 Apr 7. Eur Arch Otorhinolaryngol. 2024. PMID: 38584217
References
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous